Evidence map›Paper›PMID 39451544›Full record

ArticleCurrent issues in molecular biology2024

Protective Effects of

Gi-Bang Koo, Han Ol Kwon, Jong Han Kim, Seung Ho Lee, Sung Lye Shim, Kyoung Hwa Jang

Abstract read
In one paragraph

Article in Current issues in molecular biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Gi-Bang KooLaboratory of Efficacy Research, Korea Ginseng Corporation, Gwacheon 13840, Republic of Korea.ORCID 0009-0001-1123-1328
Han Ol KwonLaboratory of Efficacy Research, Korea Ginseng Corporation, Gwacheon 13840, Republic of Korea.
Jong Han KimLaboratory of Efficacy Research, Korea Ginseng Corporation, Gwacheon 13840, Republic of Korea.ORCID 0009-0000-1940-0862
Seung Ho LeeLaboratory of Efficacy Research, Korea Ginseng Corporation, Gwacheon 13840, Republic of Korea.
Sung Lye ShimLaboratory of Resource and Analysis, Korea Ginseng Corporation, Gwacheon 13840, Republic of Korea.
Kyoung Hwa JangLaboratory of Efficacy Research, Korea Ginseng Corporation, Gwacheon 13840, Republic of Korea.

Funding

Korea Ginseng Corporation KGC-PD 20-202
6 · The paper itself

Abstract

Sarcopenia is a condition characterized by a progressive loss of muscle mass and function which are influenced by certain factors such as aging, nutritional deficiencies, and chronic diseases. Despite numerous efforts to prevent or treat sarcopenia, effective therapeutic options for this disease remain limited. This study aims to evaluate the effects of KGC01CE treatment, a mixture of

Indexed as

Cervus elaphusEucommia ulmoidesKGC01CEmuscle atrophysarcopenia

Identifiers

PMID39451544
PMCPMC11506417

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.